1
|
Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine. J Neural Transm (Vienna) 2016; 124:57-78. [PMID: 27796511 DOI: 10.1007/s00702-016-1633-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2016] [Accepted: 10/10/2016] [Indexed: 12/15/2022]
Abstract
Evaluating each patient and animal as its own control achieves personalized medicine, which honors the hippocratic philosophy, explaining that "it is far more important to know what person has the disease than what disease the person has." Similarly, individualizing molecular signaling directly from the patient's brain in real time is essential for providing prompt, patient-based treatment as dictated by the point of care. Fortunately, nanotechnology effectively treats many neurodegenerative diseases. In particular, the new medicinal frontier for the discovery of therapy for Parkinson's disease is nanotechnology and nanobiotechnology. Indeed, the unique nanotechnology of neuromolecular imaging combined with the series of nanobiosensors enables continuous videotracking of molecular neurotransmitters in both the normal physiologic and disease states with long-term electrochemical operational stability. This nanobiotechnology is able to track a signal in real time with excellent temporal and spatial resolution directly from each patient's brain to a computer as subjects are behaving during movement, normal and/or dysfunctional including prion-like Parkinson's behavioral biometrics. Moreover, the molecular signaling performed by these nanobiosensors live streams directly online and originates from precise neuroanatomic brain sites such as, in this case, the dorsal striatum in basal ganglia. Thus, the nanobiotechnology studies discussed herein imaged neuromolecules with and without L-3,4-dihydroxyphenylalanine (L-DOPA) in dorsal striatal basal ganglia neurons. Parkinsonian and non-Parkinsonian animals were video-tracked, and images were readily seen on a laptop via a potentiostat using a semiderivative electrical circuit. Administered L-DOPA doses were 50 and 100 mg/kg intraperitoneally (ip); the same experimental paradigm was used to image and then contrast data. Results showed that the baseline release of biogenic amine molecules was significantly above detection limits in non-Parkinsonian animals. After administration of L-DOPA, biogenic amines significantly increased in these non-Parkinson's animals. Nevertheless, it is intriguing to see that L-DOPA could not enable synaptic dopamine release in Parkinson's animals, thereby demonstrating that biogenic amines are biomarkers for Parkinson's disease. Biomarkers are biochemical, genetic, or molecular measures of biological reactions. Importantly, there were other significant biomarkers present in Parkinsonian animals and absent in non-Parkinsonian animals; these were peptide neurotransmitters that include dynorphin and somatostatin in the brain with detection limits of 40 nM for dynorphin and 37 nM for somatostatin (see Table 1). Furthermore, L-DOPA significantly increased these peptide biomarkers, dynorphin and somatostatin, in Parkinson's animals. Targeting biomarkers enables new diagnostic devices and treatments for Parkinson's disease through nanotechnology and nanobiotechnology.
Collapse
|
2
|
Broderick PA, Malave LB. Cocaine Shifts the Estrus Cycle Out of Phase and Caffeine Restores It. JOURNAL OF CAFFEINE RESEARCH 2014; 4:109-113. [PMID: 25538863 DOI: 10.1089/jcr.2014.0015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Background: Sex differences in cocaine abuse are well established. Females have a higher sensitivity and thus higher vulnerability to cocaine abuse compared to males. There are many studies showing that sensitivity to cocaine reward varies during the estrus cycle. Methods: Vaginal smears were examined through a DIFF staining kit and viewed through a microscope to determine the estrus cycle stage. Smears were taken immediately before and after cocaine and/or caffeine injections. Furthermore, we suggest a new tool to analyze the estrus cycle by using electrical resistance of the vaginal mucosa. Results: In the present study, we discovered that cocaine directly induced changes in the estrus cycle. Interestingly, caffeine did not affect the estrus cycle and nor did the combination of cocaine and caffeine. We observed that caffeine blocked the cocaine-induced estrus cycle changes using conventional exfoliate cytology. Therefore, caffeine may have neuroprotective properties on the changes induced by cocaine. Conclusion: These phase changes in the estrus cycle may be the underlying cause of sex differences in cocaine addiction that can be blocked by caffeine. Thus, we propose a valuable insight into sex differences in cocaine abuse and reveal a possible treatment with antagonizing the adenosine system.
Collapse
Affiliation(s)
- Patricia A Broderick
- Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education , City College of New York, New York, New York. ; Department of Biology, City University of New York Graduate Center , New York, New York. ; Center for Advanced Technology (CAT), City University of New York , New York, New York. ; Department of Neurology, NYU Langone Medical Center , New York, New York
| | - Lauren B Malave
- Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education , City College of New York, New York, New York. ; Department of Biology, City University of New York Graduate Center , New York, New York. ; Center for Advanced Technology (CAT), City University of New York , New York, New York
| |
Collapse
|
3
|
Malave LB, Broderick PA. Caffeine's Attenuation of Cocaine-Induced Dopamine Release by Inhibition of Adenosine. JOURNAL OF CAFFEINE RESEARCH 2014; 4:35-40. [PMID: 25054079 DOI: 10.1089/jcr.2014.0004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Background: It is well known that the reinforcing properties of cocaine addiction are caused by the sharp increase of dopamine (DA) in the reward areas of the brain. However, other mechanisms have been speculated to contribute to the increase. Adenosine is one system that is associated with the sleep-wake cycle and is most important in regulating neuronal activity. Thus, more and more evidence is pointing to its involvement in regulating DA release. The current study set out to examine the role of adenosine in cocaine-induced DA release. Methods: Increasing doses of cocaine, caffeine, and their combination, as well as, 8-cyclopentyltheophylline (CPT), an adenosine A1 antagonist (alone and in combination with cocaine) were used to denote a response curve. A novel biosensor, the BRODERICK PROBE® was implanted in the nucleus accumbens to image the drug-induced surge of DA release in vivo, in the freely moving animal in real time. Results: Combinations of cocaine and caffeine were observed to block the increased release of DA moderately after administration of the low dose (2.5 mg/kg cocaine and 12.5 mg/kg caffeine) and dramatically after administration of the high dose (10 mg/kg cocaine and 50 mg/kg caffeine), suggesting neuroprotection. Similarly, CPT and cocaine showed a decreased DA surge when administered in combination. Thus, the low and high dose of a nonselective adenosine antagonist, caffeine, and a moderate dose of a selective adenosine antagonist, CPT, protected against the cocaine-induced DA release. Conclusions: These results show a significant interaction between adenosine and DA release and suggest therapeutic options for cocaine addiction and disorders associated with DA dysfunction.
Collapse
Affiliation(s)
- Lauren B Malave
- Department of Physiology, Pharmacology and Neuroscience, The Sophie Davis School, The City College of New York , New York, New York. ; Department of Biology, CUNY Graduate Center , New York, New York. ; Center for Advanced Technology (CAT) CUNY , New York, New York
| | - Patricia A Broderick
- Department of Physiology, Pharmacology and Neuroscience, The Sophie Davis School, The City College of New York , New York, New York. ; Department of Biology, CUNY Graduate Center , New York, New York. ; Center for Advanced Technology (CAT) CUNY , New York, New York. ; Department of Neurology, NYU Langone Medical Center , New York, New York
| |
Collapse
|
4
|
Lowe CR. The future: biomarkers, biosensors, neuroinformatics, and e-neuropsychiatry. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2012; 101:375-400. [PMID: 22050860 DOI: 10.1016/b978-0-12-387718-5.00015-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The emergence of molecular biomarkers for psychological, psychiatric, and neurodegenerative disorders is beginning to change current diagnostic paradigms for this debilitating family of mental illnesses. The development of new genomic, proteomic, and metabolomic tools has created the prospect of sensitive and specific biochemical tests to replace traditional pen-and-paper questionnaires. In the future, the realization of biosensor technologies, point-of-care testing, and the fusion of clinical biomarker data, electroencephalogram, and MRI data with the patient's past medical history, biopatterns, and prognosis may create personalized bioprofiles or fingerprints for brain disorders. Further, the application of mobile communications technology and grid computing to support data-, computation- and knowledge-based tasks will assist disease prediction, diagnosis, prognosis, and compliance monitoring. It is anticipated that, ultimately, mobile devices could become the next generation of personalized pharmacies.
Collapse
Affiliation(s)
- Christopher R Lowe
- Department of Chemical Engineering and Biotechnology, Institute of Biotechnology, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
5
|
Biosensors for brain trauma and dual laser doppler flowmetry: enoxaparin simultaneously reduces stroke-induced dopamine and blood flow while enhancing serotonin and blood flow in motor neurons of brain, in vivo. SENSORS 2010; 11:138-61. [PMID: 22346571 PMCID: PMC3274119 DOI: 10.3390/s11010013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2010] [Revised: 11/18/2010] [Accepted: 12/06/2010] [Indexed: 12/16/2022]
Abstract
Neuromolecular Imaging (NMI) based on adsorptive electrochemistry, combined with Dual Laser Doppler Flowmetry (LDF) is presented herein to investigate the brain neurochemistry affected by enoxaparin (Lovenox(®)), an antiplatelet/antithrombotic medication for stroke victims. NMI with miniature biosensors enables neurotransmitter and neuropeptide (NT) imaging; each NT is imaged with a response time in milliseconds. A semiderivative electronic reduction circuit images several NT's selectively and separately within a response time of minutes. Spatial resolution of NMI biosensors is in the range of nanomicrons and electrochemically-induced current ranges are in pico- and nano-amperes. Simultaneously with NMI, the LDF technology presented herein operates on line by illuminating the living brain, in this example, in dorso-striatal neuroanatomic substrates via a laser sensor with low power laser light containing optical fiber light guides. NMI biotechnology with BRODERICK PROBE(®) biosensors has a distinct advantage over conventional electrochemical methodologies both in novelty of biosensor formulations and on-line imaging capabilities in the biosensor field. NMI with unique biocompatible biosensors precisely images NT in the body, blood and brain of animals and humans using characteristic experimentally derived half-wave potentials driven by oxidative electron transfer. Enoxaparin is a first line clinical treatment prescribed to halt the progression of acute ischemic stroke (AIS). In the present studies, BRODERICK PROBE(®) laurate biosensors and LDF laser sensors are placed in dorsal striatum (DStr) dopaminergic motor neurons in basal ganglia of brain in living animals; basal ganglia influence movement disorders such as those correlated with AIS. The purpose of these studies is to understand what is happening in brain neurochemistry and cerebral blood perfusion after causal AIS by middle cerebral artery occlusion in vivo as well as to understand consequent enoxaparin and reperfusion effects actually while enoxaparin is inhibiting blood clots to alleviate AIS symptomatology. This research is directly correlated with the medical and clinical needs of stroke victims. The data are clinically relevant, not only to movement dysfunction but also to the depressive mood that stroke patients often endure. These are the first studies to image brain neurotransmitters while any stroke medications, such as anti-platelet/anti-thrombotic and/or anti-glycoprotein are working in organ systems to alleviate the debilitating consequences of brain trauma and stroke/brain attacks.
Collapse
|
6
|
Broderick PA, Kolodny EH. Real Time Imaging of Biomarkers in the Parkinson's Brain Using Mini-Implantable Biosensors. II. Pharmaceutical Therapy with Bromocriptine. Pharmaceuticals (Basel) 2009; 2:236-249. [PMID: 27713237 PMCID: PMC3978546 DOI: 10.3390/ph2030236] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2009] [Revised: 12/12/2009] [Accepted: 12/16/2009] [Indexed: 11/16/2022] Open
Abstract
We used Neuromolecular Imaging (NMI) and trademarked BRODERICK PROBE® mini-implantable biosensors, to selectively and separately detect neurotransmitters in vivo, on line, within seconds in the dorsal striatal brain of the Parkinson's Disease (PD) animal model. We directly compared our results derived from PD to the normal striatal brain of the non-Parkinson's Disease (non-PD) animal. This advanced biotechnology enabled the imaging of dopamine (DA), serotonin (5-HT), homovanillic acid (HVA) a metabolite of DA, L-tryptophan (L-TP) a precursor to 5-HT and peptides, dynorphin A 1-17 (Dyn A) and somatostatin (somatostatin releasing inhibitory factor) (SRIF). Each neurotransmitter and neurochemical was imaged at a signature electroactive oxidation/half-wave potential in dorsal striatum of the PD as compared with the non-PD animal. Both endogenous and bromocriptine-treated neurochemical profiles in PD and non-PD were imaged using the same experimental paradigm and detection sensitivities. Results showed that we have found significant neurotransmitter peptide biomarkers in the dorsal striatal brain of endogenous and bromocriptine-treated PD animals. The peptide biomarkers were not imaged in dorsal striatal brain of non-PD animals, either endogenously or bromocriptine-treated. These findings provide new pharmacotherapeutic strategies for PD patients. Thus, our findings are highly applicable to the clinical treatment of PD.
Collapse
Affiliation(s)
- Patricia A Broderick
- Department of Physiology & Pharmacology, Sophie Davis Sch. Biomed. Edu., CCNY, New York, NY 10031, USA.
- Departments of Biology, Psychology, CUNY Grad. Sch., New York, NY 10031, USA.
- Department of Neurology, NYU Sch. Med., Langone Med. Ctr., NYU Langone Comprehensive Epilepsy Ctr., New York, NY 10016, USA.
| | - Edwin H Kolodny
- Department of Neurology, NYU Sch. Med., Langone Med. Ctr., NYU Langone Comprehensive Epilepsy Ctr., New York, NY 10016, USA
| |
Collapse
|
7
|
Park JY, Lee YS, Chang BY, Karthikeyan S, Kim KS, Kim BH, Park SM. (R)-Lipo-Diaza-18-Crown-6 Self-Assembled Monolayer as a Selective Serotonin Receptor. Anal Chem 2009; 81:3843-50. [DOI: 10.1021/ac900220n] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Jin-Young Park
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| | - Yoon-Suk Lee
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| | - Byoung-Yong Chang
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| | - S. Karthikeyan
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| | - Kwang S. Kim
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| | - Byeang Hyean Kim
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| | - Su-Moon Park
- Department of Chemistry and Center for Integrated Molecular Systems, Pohang University of Science and Technology, Pohang 790-784, Korea, and School of Energy Engineering, Ulsan Institute of Science & Technology, Ulsan 689-805, Korea
| |
Collapse
|